Market Cap | 438.72M | P/E | - | EPS this Y | -12.10% | Ern Qtrly Grth | - |
Income | -70.8M | Forward P/E | -5.59 | EPS next Y | -39.20% | 50D Avg Chg | 53.00% |
Sales | 46.02M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 143.00% |
Dividend | N/A | Price/Book | 8.39 | EPS next 5Y | - | 52W High Chg | -1.00% |
Recommedations | 1.80 | Quick Ratio | 5.25 | Shares Outstanding | 52.08M | 52W Low Chg | 484.00% |
Insider Own | 0.98% | ROA | -17.24% | Shares Float | 30.35M | Beta | 1.68 |
Inst Own | 104.09% | ROE | -39.04% | Shares Shorted/Prior | 6.54M/6.58M | Price | 12.79 |
Gross Margin | -49.93% | Profit Margin | -153.84% | Avg. Volume | 515,188 | Target Price | 43.67 |
Oper. Margin | -108.03% | Earnings Date | May 2 | Volume | 859,690 | Change | 0.71% |
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
HC Wainwright & Co. | Buy | Mar 8, 24 |
Mizuho | Buy | Feb 16, 24 |
JP Morgan | Overweight | Jan 22, 24 |
HC Wainwright & Co. | Buy | Jan 16, 24 |
Capital One | Overweight | Dec 11, 23 |
Mizuho | Buy | Dec 7, 23 |
HC Wainwright & Co. | Buy | Dec 5, 23 |
HC Wainwright & Co. | Buy | Nov 2, 23 |
Mizuho | Buy | Nov 2, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Jones David Scott | SVP & Chief Commerci.. SVP & Chief Commercial Officer | Jan 26 | Sell | 25.36 | 26,017 | 659,791 | 37,962 | 01/29/24 |
Jones David Scott | SVP & Chief Commerci.. SVP & Chief Commercial Officer | Jan 26 | Option | 8.08 | 26,017 | 210,217 | 63,979 | 01/29/24 |
Paggiarino Dario A. | Chief Medical Office.. Chief Medical Officer | Jan 25 | Sell | 25 | 600 | 15,000 | 36,505 | 01/29/24 |
Paggiarino Dario A. | Chief Medical Office.. Chief Medical Officer | Jan 25 | Option | 13.02 | 600 | 7,812 | 37,105 | 01/29/24 |
Jones David Scott | SVP & Chief Commerci.. SVP & Chief Commercial Officer | Jan 24 | Sell | 25.01 | 11,900 | 297,619 | 37,962 | 01/26/24 |
Jones David Scott | SVP & Chief Commerci.. SVP & Chief Commercial Officer | Jan 24 | Option | 8.08 | 11,900 | 96,152 | 38,562 | 01/26/24 |
Paggiarino Dario A. | Chief Medical Office.. Chief Medical Officer | Jan 23 | Sell | 25.01 | 16,386 | 409,814 | 36,505 | 01/25/24 |
Paggiarino Dario A. | Chief Medical Office.. Chief Medical Officer | Jan 23 | Option | 13.02 | 16,386 | 213,346 | 47,756 | 01/25/24 |
Lurker Nancy | Executive Vice Chair Executive Vice Chair | Jan 23 | Sell | 24.97 | 35,000 | 873,950 | 135,441 | 01/25/24 |
Jones David Scott | SVP & Chief Commerci.. SVP & Chief Commercial Officer | Jan 22 | Sell | 23.73 | 35,066 | 832,116 | 37,962 | 01/24/24 |
Jones David Scott | SVP & Chief Commerci.. SVP & Chief Commercial Officer | Jan 22 | Option | 9.44 | 35,066 | 331,023 | 38,862 | 01/24/24 |
Ocumension Therapeutics | Director Director | Jan 11 | Sell | 19.45 | 1,910,500 | 37,159,225 | 100,221 | 01/16/24 |
Liu Ye | Director Director | Jan 11 | Sell | 19.45 | 1,910,500 | 37,159,225 | 100,221 | 01/16/24 |
Paggiarino Dario A. | Chief Medical Office.. Chief Medical Officer | Jan 08 | Sell | 21.13 | 22,913 | 484,152 | 36,505 | 01/10/24 |
Paggiarino Dario A. | Chief Medical Office.. Chief Medical Officer | Jan 08 | Option | 3.26 | 22,913 | 74,696 | 59,418 | 01/10/24 |
Paggiarino Dario A. | Chief Medical Office.. Chief Medical Officer | Dec 13 | Sell | 20 | 1,458 | 29,160 | 25,707 | 12/15/23 |
Paggiarino Dario A. | Chief Medical Office.. Chief Medical Officer | Dec 13 | Option | 10.13 | 1,458 | 14,770 | 27,165 | 12/15/23 |
Ocumension Therapeutics | Director Director | Dec 05 | Sell | 19.16 | 1,000,000 | 19,160,000 | 2,010,721 | 12/07/23 |
Liu Ye | Director Director | Dec 05 | Sell | 19.16 | 1,000,000 | 19,160,000 | 2,010,721 | 12/07/23 |
Pine Michael Craig | Chief Corp Dev.&Stra.. Chief Corp Dev.&Strat. Officer | Dec 04 | Sell | 22 | 45,000 | 990,000 | 5,343 | 12/06/23 |
Pine Michael Craig | Chief Corp Dev.&Stra.. Chief Corp Dev.&Strat. Officer | Dec 04 | Option | 12.62 | 45,000 | 567,900 | 50,343 | 12/06/23 |
Paggiarino Dario A. | Chief Medical Office.. Chief Medical Officer | Dec 04 | Sell | 22 | 30,625 | 673,750 | 25,707 | 12/06/23 |
Paggiarino Dario A. | Chief Medical Office.. Chief Medical Officer | Dec 04 | Option | 10.13 | 30,625 | 310,231 | 56,332 | 12/06/23 |
Lurker Nancy | Executive Vice Chair Executive Vice Chair | Dec 04 | Sell | 20.76 | 20,000 | 415,200 | 170,559 | 12/06/23 |
Cormorant Asset Management, LP | 10% Owner 10% Owner | Dec 04 | Buy | 26.82 | 1,919,057 | 51,469,109 | 5,450,000 | 12/06/23 |
EW Healthcare Partners, L.P. | 10% Owner 10% Owner | Sep 01 | Sell | 9.8991 | 20,000 | 197,982 | 3,490,921 | 09/06/23 |
EW Healthcare Partners, L.P. | 10% Owner 10% Owner | Aug 30 | Sell | 10.87 | 139,471 | 1,516,050 | 3,510,921 | 09/01/23 |
EW Healthcare Partners, L.P. | 10% Owner 10% Owner | Aug 28 | Sell | 11.34 | 148,712 | 1,686,394 | 3,650,392 | 08/30/23 |
EW Healthcare Partners, L.P. | 10% Owner 10% Owner | Aug 24 | Sell | 10.91 | 223,936 | 2,443,142 | 3,799,104 | 08/30/23 |
EW Healthcare Partners, L.P. | 10% Owner 10% Owner | Aug 22 | Sell | 13.84 | 167,881 | 2,323,473 | 4,023,040 | 08/24/23 |
Zaderej Karen L. | Director Director | Jul 11 | Option | 0.00 | 2,000 | 2,000 | 07/12/23 | |
ADAMIS ANTHONY P | Director Director | Jun 23 | Option | 0.00 | 2,000 | 2,000 | 06/26/23 | |
Liu Ye | Director Director | May 30 | Sell | 6.00 | 1 | 6 | 3,010,721 | 05/31/23 |
Lurker Nancy | President & CEO President & CEO | Feb 28 | Option | 0.00 | 12,466 | 150,281 | 03/02/22 | |
Landis John B. | Director Director | Feb 09 | Option | 0.00 | 2,500 | 8,400 | 02/11/22 | |
GUYER DAVID R | Director Director | Feb 09 | Option | 0.00 | 2,500 | 4,400 | 02/11/22 | |
DICICCO WENDY F | Director Director | Feb 09 | Option | 0.00 | 2,500 | 4,400 | 02/11/22 | |
ANDO GORAN | Director Director | Feb 09 | Option | 0.00 | 2,750 | 4,900 | 02/11/22 |